(Q39139792)

9 September 2017

title

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors (English)

1 reference

9 September 2017

1 reference

Avi Ashkenazi

1

1 reference

9 September 2017

Wayne J Fairbrother

series ordinal

2

1 reference

9 September 2017

Joel D Leverson

series ordinal

3

1 reference

9 September 2017

Andrew J Souers

series ordinal

4

1 reference

9 September 2017

publication date

17 February 2017

1 reference

Nature Reviews Drug Discovery

9 September 2017

published in

1 reference

9 September 2017

volume

16

1 reference

9 September 2017

issue

4

1 reference

9 September 2017

page(s)

273-284

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd.2016.253

9 September 2017

exact match

0 references

cites work

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Cell death: critical control points

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Death receptors: signaling and modulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

BH3-only proteins: Orchestrators of apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

31 March 2020

The BCL-2 family reunion

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Dysregulation of apoptosis genes in hematopoietic malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

BCL-2 family antagonists for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Molecular basis of Bcl-X(L)-p53 interaction: insights from molecular dynamics simulations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Discovering high-affinity ligands for proteins: SAR by NMR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Bcl-2 family proteins are essential for platelet survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Programmed anuclear cell death delimits platelet life span.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Game, set, match for factor VIII mismatch?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Getting a handle on hereditary CEBPA mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Inflammation rapidly reorganizes mouse bone marrow B cells and their environment in conjunction with early IgM responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Structure-guided design of a selective BCL-X(L) inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Structure-Guided Rescaffolding of Selective Antagonists of BCL-X L

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Mito-priming as a method to engineer Bcl-2 addiction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Delving deeper: MCL-1's contributions to normal and cancer biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

The landscape of somatic copy-number alteration across human cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Rational Design of Proteolytically Stable, Cell-Permeable Peptide-Based Selective Mcl-1 Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Structure-Guided Rational Design of α/β-Peptide Foldamers with High Affinity for BCL-2 Family Prosurvival Proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Small molecule Mcl-1 inhibitors for the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Evaluation and critical assessment of putative MCL-1 inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Bh3 induced conformational changes in Bcl-Xl revealed by crystal structure and comparative analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.253

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

31 March 2020

1 reference

12 December 2020

Overview of cell death signaling pathways

1 reference

12 December 2020

Expression of bcl-xL can confer a multidrug resistance phenotype.

1 reference

12 December 2020

An informatics approach identifying markers of chemosensitivity in human cancer cell lines.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2016.253

1 reference

9 September 2017

1 reference